Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 13/20 | 0.62 |
| ▸ | MAP2K4 | P45985 | 4/20 | 0.62 |
| ▸ | MAPKAPK3 | Q16644 | 2/20 | 0.62 |
| ▸ | MAPK6 | Q16659 | 2/20 | 0.62 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.62 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.62 |
| ▸ | MAPK3 | P27361 | 5/20 | 0.58 |
| ▸ | TTK | P33981 | 1/20 | 0.55 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23050281 | 0.88 | MAPK1 (0.62) | MAPK1MAP2K4MAPKAPK3MAPK6MAPKAPK2 | |
| SCHEMBL9987156 | 0.88 | MAPK1 (0.62) | MAPK1MAP2K4MAPKAPK3MAPK6MAPK3 | |
| SCHEMBL12074349 | 0.84 | TTK (0.57) | MAPK1MAP2K4MAPKAPK3MAPK6MAPKAPK2 | |
| SCHEMBL12074347 | 0.84 | MAPK1 (0.58) | MAPK1MAP2K4MAPKAPK3MAPK6MAPKAPK2 | |
| SCHEMBL23050172 | 0.83 | MAPK1 (0.58) | MAPK1MAPK3 | |
| SCHEMBL29511803 | 0.83 | MAPK1 (0.58) | MAPK1MAPK3 | |
| SCHEMBL8437332 | 0.82 | MAP2K4 (0.84) | MAPK1MAP2K4MAPKAPK3MAPK6MAPKAPK2 | |
| SCHEMBL9987358 | 0.82 | MAPK1 (0.66) | MAPK1MAP2K4MAPKAPK3MAPK6MAPKAPK2 | |
| SCHEMBL21338430 | 0.82 | MAPK1 (0.53) | MAPK1MAP2K4MAPKAPK3MAPK6MAPKAPK2 | |
| SCHEMBL23559721 | 0.80 | MAP2K4 (0.58) | MAPK1MAP2K4MAPKAPK3MAPK6MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2654748-A1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-10-30 | — | — | EP | claimed |
| WO-2012087772-A1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | SCHERING CORPORATION (US) | 2012-06-28 | — | — | WO | claimed |
| EP-3337787-B1 | 1H-PYRAZOLO[3,4-B]PYRIDINE, 1H-THIENO[2,3-C]PYRAZOLE AND 1H-INDAZOLE CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS EXTRACELLULAR SIGNAL-REGULATED KINASES (ERK) INHIBITORS FOR TREATING CANCER | JS INNOPHARM SHANGHAI LTD (CN) | 2021-03-03 | — | — | EP | disclosed |
| EP-2654748-B1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2016-07-27 | — | — | EP | disclosed |
| US-9351965-B2 | Indazole derivatives useful as ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20130261125-A1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2013-10-03 | — | — | US | disclosed |
| WO-2011163330-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261125-A1 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS | MAPK3, MAPK1, MAP3K1 | MAPK1 2/4885MAP2K4 164/4885MAPKAPK3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.